

Astellas Included in Dow Jones Sustainability Asia Pacific Index for Second Consecutive Year

Tokyo, Japan, September 26, 2012 - [Astellas Pharma Inc.](http://www.astellas.com) (Tokyo:4503, "Astellas") announced that it has been selected for the second consecutive year in the Dow Jones Sustainability Asia Pacific Index ("DJSI Asia Pacific"), the Asia Pacific version of the Dow Jones Sustainability Index* ("DJSI"), one of the world's premier indexes for social responsible investment (SRI).

The DJSI, jointly compiled by Dow Jones & Company of the United States and Sustainable Asset Management (SAM) AG of Switzerland** is a leading SRI index which assesses and selects leading sustainability-driven companies in terms of economic, environmental, and social criteria. Specifically designed for companies in the developed Asia Pacific markets including Japan, the DJSI Asia Pacific has selected 154 companies, including 74 Japanese companies, which are leading the way in terms of sustainability among the 600 companies in the region.

Astellas' CSR-based management program is a means through which it seeks to achieve sustained enhancement of its enterprise value while remaining acutely aware of its social responsibilities, taking a broad view that considers economics, society, and humanity so that it can exist not just as a market entity, but also as a valuable member of society. Astellas promotes this as fundamental policy for its corporate activities.

Astellas, as a global pharmaceutical company, will continue committing to fulfill its social responsibility by promoting further CSR-based management aspiring to practice its *raison d'être* "contribute toward improving the health of people around the world through the provision of innovative and reliable pharmaceutical products."

*Dow Jones Sustainability Asia Pacific Index URL : <http://www.sustainability-indexes.com/>

**SAM : An asset management consulting firm in Switzerland which assesses sustainability-driven companies in the index.

###

For inquiries or additional information
Astellas Pharma Inc. Corporate Communications Tel: +81-3-3244-3201 Fax: +81-3-5201-7473 http://www.astellas.com/en